← Leaderboards
Rohit Loomba
Indiana University Indianapolis
$20,349,897
Attributed
$29,923,217
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,923,217 · 11
By mechanism
R01$12,877,451 · 3
U01$11,208,148 · 3
P01$2,785,121 · 1
P30$1,957,969 · 2
K23$721,440 · 1
T32$373,088 · 1
Top collaborators
- Naga P. Chalasani5 shared
- Tatiana Kisseleva5 shared
- Sheldon Robert Morris5 shared
- Claude B Sirlin5 shared
- Mark Sebastian Sulkowski5 shared
- Lars Eckmann1 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Mark Sebastian Sulkowski$12,713,668
Others in their field
Top investigators on “Liver”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Mark A Kay · Stanford University$49,905,067
Research focus
LiverCohortUnited StatesFibrosisClinical ResearchParticipantLiver DiseasesNonalcoholic SteatohepatitisAdultCirrhosisChronic Liver DiseaseNon-Alcoholic Fatty Liver DiseaseHepaticLiver BiopsyLiver TransplantationDisease ProgressionDiagnosisProspectiveCaliforniaSiteBiological MarkersInflammationFutureAffect
Grant awards (48)
Multidisciplinary Research Training in Digestive Physiology and Diseases$373,088
T32 · FY2025 · DK
San Diego Cirrhosis Clinical Research Network$359,789
U01 · FY2025 · DK · contact PI
Human Translational Core$311,529
P30 · FY2025 · DK · contact PI
Clinical Research on Nonalcoholic Fatty Liver Disease$250,000
U01 · FY2025 · DK · contact PI
Ancillary Studies of NAFLD and NASH in HIV infected Adults$1,464,756
R01 · FY2024 · DK
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease$711,945
U01 · FY2024 · AA · contact PI
Role of liver fat and fibrosis in human CVD risk phenotypes.$540,686
P01 · FY2024 · HL · contact PI
San Diego Cirrhosis Clinical Research Network$344,119
U01 · FY2024 · DK · contact PI
Human Translational Core$311,529
P30 · FY2024 · DK · contact PI
Clinical Research on Nonalcoholic Fatty Liver Disease$250,000
U01 · FY2024 · DK · contact PI
San Diego Cirrhosis Clinical Research Network$60,194
U01 · FY2024 · DK · contact PI
Ancillary Studies of NAFLD and NASH in HIV infected Adults$1,542,615
R01 · FY2023 · DK
Clinical Research on Nonalcoholic Fatty Liver Disease$974,693
U01 · FY2023 · DK · contact PI
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease$742,984
U01 · FY2023 · AA · contact PI
Role of liver fat and fibrosis in human CVD risk phenotypes.$538,353
P01 · FY2023 · HL · contact PI
San Diego Cirrhosis Clinical Research Network$502,075
U01 · FY2023 · DK · contact PI
Human Translational Core$268,959
P30 · FY2023 · DK · contact PI
Ancillary Studies of NAFLD and NASH in HIV infected Adults$1,558,981
R01 · FY2022 · DK
Clinical Research on Nonalcoholic Fatty Liver Disease$921,115
U01 · FY2022 · DK · contact PI
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease$699,515
U01 · FY2022 · AA · contact PI
Non-invasive screening of diabetics for advanced fibrosis due to NAFLD$567,065
R01 · FY2022 · DK · contact PI
Role of liver fat and fibrosis in human CVD risk phenotypes.$565,448
P01 · FY2022 · HL · contact PI
San Diego Cirrhosis Clinical Research Network$331,018
U01 · FY2022 · DK · contact PI
Human Translational Core$268,960
P30 · FY2022 · DK · contact PI
Ancillary Studies of NAFLD and NASH in HIV infected Adults$1,566,039
R01 · FY2021 · DK
Clinical Research on Nonalcoholic Fatty Liver Disease$1,034,705
U01 · FY2021 · DK · contact PI
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease$781,354
U01 · FY2021 · AA · contact PI
Role of liver fat and fibrosis in human CVD risk phenotypes.$570,618
P01 · FY2021 · HL · contact PI
Non-invasive screening of diabetics for advanced fibrosis due to NAFLD$542,792
R01 · FY2021 · DK · contact PI
San Diego Cirrhosis Clinical Research Network$352,110
U01 · FY2021 · DK · contact PI
Human Translational Core$268,817
P30 · FY2021 · DK · contact PI
Ancillary Studies of NAFLD and NASH in HIV infected Adults$1,703,139
R01 · FY2020 · DK
Clinical Research on Nonalcoholic Fatty Liver Disease$1,408,077
U01 · FY2020 · DK · contact PI
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease$782,852
U01 · FY2020 · AA · contact PI
Role of liver fat and fibrosis in human CVD risk phenotypes.$570,016
P01 · FY2020 · HL · contact PI
Non-invasive screening of diabetics for advanced fibrosis due to NAFLD$564,086
R01 · FY2020 · DK · contact PI
Human Translational Core$260,066
P30 · FY2020 · DK · contact PI
Clinical Research on Nonalcoholic Fatty Liver Disease$701,603
U01 · FY2019 · DK · contact PI
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD$642,595
R01 · FY2019 · DK
Human Translational Core$268,109
P30 · FY2019 · DK · contact PI
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD$666,621
R01 · FY2018 · DK
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD$665,303
R01 · FY2017 · DK
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD$679,686
R01 · FY2016 · DK
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD$713,773
R01 · FY2015 · DK
GENETIC EPIDEMIOLOGY OF NONALCOHOLIC FATTY LIVER DISEASE$180,360
K23 · FY2014 · DK · contact PI
GENETIC EPIDEMIOLOGY OF NONALCOHOLIC FATTY LIVER DISEASE$180,360
K23 · FY2013 · DK · contact PI
GENETIC EPIDEMIOLOGY OF NONALCOHOLIC FATTY LIVER DISEASE$180,360
K23 · FY2012 · DK · contact PI
GENETIC EPIDEMIOLOGY OF NONALCOHOLIC FATTY LIVER DISEASE$180,360
K23 · FY2011 · DK · contact PI